<DOC>
	<DOCNO>NCT02201030</DOCNO>
	<brief_summary>This study assess immunogenicity safety primary vaccination NBP606 compare exist commercial vaccine , give concomitantly routine pediatric vaccination .</brief_summary>
	<brief_title>Immunogenicity Safety Study NBP606 Healthy Infants</brief_title>
	<detailed_description />
	<mesh_term>Pneumococcal Infections</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>Healthy Infants 42 98 day age ( approximately 2 month ) time enrollment . The LAR ( Legally Authorized Representative ) understand requirement study voluntarily consent participate study . Known hypersensitivity component pneumococcal vaccine Any confirm suspected immunosuppressive immunodeficient condition Coagulation disorder contraindicate IM ( intramuscular ) vaccination Subject receive licensed vaccine ( include BCG Hepatitis B ) Participation another study</criteria>
	<gender>All</gender>
	<minimum_age>42 Days</minimum_age>
	<maximum_age>98 Days</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>